KnowTheStock
Log inCreate free account

Bio-Techne Corp

TECH
S&P 500Biological Product (except Diagnostic) Manufacturing · NASDAQ
$70.90last close · market cap 11.13 Billion
Compare with…
52.9SCORE / 100
Our verdictSELLModerate Growth but Declining, Stock Price Very HighFY Ending 2026-06-30 · trend negative

Why Sell

Income statement, balance sheet and cash flow are moderate.

Next earnings: 2026-11-04, EPS Forecast: $0.38

What is strong
  • Operating Income Growth is 146.34%
  • Net Income Growth is 147.86%
  • Earnings Per Share (EPS) Growth is 152.17%
  • Net Margin is 14.97%
  • Current Asset to Current Liability Ratio is 4.55
  • Debt Ratio is 0.07
  • Current Debt to Net Income Ratio is 0.0
  • Total Debt to Total Assets Ratio is 0.08
  • Capital Expenditure is Low
  • Net Increase in Cash is Positive
What to watch
  • Revenue Growth is -0.38%
  • Cash from Operations Growth is 1.57%
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Hold to Sell in the Sep 2023 quarter: 69.5 → 62.3 (-7.2). This quarter: +4.6.

4050607080Sep 2022Mar 2026

What the score is made of

Income statement41.8 +1.4
Balance sheet56.3 +2.1
Cash flow53.9 +20.5

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)1.22 Billion-0.38 % growth
EPS1.16152.17 % growth
Profit margin14.97 %Profit per $1 of sales
P-E ratio—Not available
Market cap11.13 BillionShares × price
Debt-equity ratio0.09Leverage
Dividend0.32Per share, annual
Next earnings2026-11-04EPS forecast $0.38
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About Bio-Techne Corp

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

CEO
Charles Kummeth
Employees
1,595
Sector
Manufacturing
Exchange
NASDAQ
bio-techne.com

Similar stocks

Loading…